We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

25 hedge funds and large institutions have $8.74M invested in Evoke Pharma in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

76% more capital invested

Capital invested by funds: $4.96M → $8.74M (+$3.78M)

64% more call options, than puts

Call options by funds: $1.36M | Put options by funds: $825K

32% more funds holding

Funds holding: 19 → 25 (+6)

0.01% more ownership

Funds ownership: 0.04% → 0.05% (+0.01%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
25
Holders Change
+6
Holders Change %
+31.58%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
3
Reduced
4
Closed
3
Calls
$1.36M
Puts
$825K
Net Calls
+$532K
Net Calls Change
+$532K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.67M
2
Morgan Stanley
Morgan Stanley
New York
+$294K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$271K
4
Citadel Advisors
Citadel Advisors
Florida
+$101K
5
Renaissance Technologies
Renaissance Technologies
New York
+$98.9K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$315K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$152K
3
Goldman Sachs
Goldman Sachs
New York
-$125K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$22K
5
UCFA
United Capital Financial Advisors
Texas
-$7.02K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.85M +$1.67M +2,617 +57%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$722K -$152K -239 -18%
BlackRock
3
BlackRock
New York
$601K -$315K -494 -36%
Creative Planning
4
Creative Planning
Kansas
$469K – – –
Morgan Stanley
5
Morgan Stanley
New York
$436K +$294K +461 +251%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$287K +$271K +425 New
Northern Trust
7
Northern Trust
Illinois
$175K -$638 -1 -0.4%
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$172K – – –
Commonwealth Equity Services
9
Commonwealth Equity Services
Massachusetts
$151K – – –
WA
10
Wambolt & Associates
Colorado
$150K – – –
CAN
11
Cetera Advisor Networks
California
$142K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$108K +$101K +159 New
Renaissance Technologies
13
Renaissance Technologies
New York
$105K +$98.9K +155 New
SM
14
Sabby Management
Florida
$105K +$98.9K +155 New
Charles Schwab
15
Charles Schwab
California
$68K +$63.8K +100 New
UCFA
16
United Capital Financial Advisors
Texas
$66K -$7.02K -11 -10%
UBS Group
17
UBS Group
Switzerland
$47K +$42.1K +66 +1,650%
TRCT
18
Tower Research Capital (TRC)
New York
$34K +$31.9K +50 New
Group One Trading
19
Group One Trading
Illinois
$30K +$28.7K +45 New
DWA
20
Dorsey Wright & Associates
California
$8K +$7.02K +11 New
LC
21
Lindbrook Capital
California
$5K – – –
Federated Hermes
22
Federated Hermes
Pennsylvania
$4K +$3.19K +5 New
Citigroup
23
Citigroup
New York
$2K – – –
Osaic Holdings
24
Osaic Holdings
Arizona
$2K – – –
Wells Fargo
25
Wells Fargo
California
$1K – – –
1
2

EVOK Hedge Fund Activity: Q3 2020 in Review

25 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2020, worth a combined $8.74M — up 76% from $4.96M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new EVOK positions and 3 closed out — a net gain of 6 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.67M. The largest seller was BlackRock, cutting an estimated $315K.

  • 25 institutional investors held Evoke Pharma (EVOK) as of Q3 2020, up from 19 in Q2 2020.
  • Funds reported $8.74M of Evoke Pharma stock for Q3 2020, up 76% quarter-over-quarter.
  • 9 funds opened new Evoke Pharma positions in Q3 2020 and 3 closed out, a net change of +6 holders.
  • The largest Evoke Pharma buyer in Q3 2020 was Vanguard Group, an estimated $1.67M added.
  • The largest Evoke Pharma seller in Q3 2020 was BlackRock, an estimated $315K sold.

Based on aggregated 13F filings for Q3 2020.